|  |  |  |
| --- | --- | --- |
| **Variable name** | **Definition** | **Values** |
| setting | Setting of data collection: | 1, Cruise ship  2, Hospital  3, Traveler/evacuee from an affected area  6, Contact tracing  7, Health care worker  9, Family cluster  88, Other |
| setting 2 | Setting 2 [used in Q1, Q2 analysis] | 1, 1. Contact investigation  2, 2. Contact investigation, aggregated  3, 3. Outbreak investigation  4, 4. Statistical model  5, 5. Screening  6, 6. Hospitalised adults  7, 7. Hospitalised children  8, 8. Hospitalised children and adults  9, 9. Screening: institutional setting  10, 10. Screening: community setting  11, 11. Screening: occupational |
| q1\_nclus | Number of clusters described: | 1, One cluster  2, Two clusters |
| q1\_c1\_event | Number of individuals that were asymptomatic throughout infection: |  |
| q1\_c1\_total | Total number of individuals (denominator): | - |
| q1\_c2\_event | Number of individuals that were asymptomatic throughout infection [cluster2]: | - |
| q1\_c2\_total | Total number of individuals (denominator) [cluster2]: | - |
| q1\_c3\_event | Number of individuals that were asymptomatic throughout infection [cluster3]: | - |
| q1\_c3\_total | Total number of individuals (denominator) [cluster3]: | - |
| comment\_q1 | Comments: | - |
| source | Source: | 1, MedRxiv  2, BioRxiv  3, EMBASE  4, PubMed  5, Other |
| year | Publication year: |  |
| country | Country: | 1, Afghanistan  2, Albania  3, Algeria  4, Andorra  5, Angola  6, Antigua and Barbuda  7, Argentina  8, Armenia  9, Aruba  10, Australia  11, Austria  12, Azawad  13, Azerbaijan  14, Bahamas  15, Bahrain  16, Bangladesh  17, Barbados  18, Belarus  19, Belgium  20, Belize  21, Benin  22, Bermuda  23, Bhutan  24, Bolivia  25, Bosnia and Herzegovina  26, Botswana  27, Brazil  28, Brunei  29, Bulgaria  30, Burkina Faso  31, Burundi  32, Cambodia  33, Cameroon  34, Canada  35, Cape Verde  36, Central African Republic  37, Chad  38, Chechnya  39, Chile  40, China  41, Colombia  42, Comoros  43, Congo  44, Costa Rica  45, Côte d'Ivoire  46, Croatia  47, Cuba  48, Curaçao  49, Cyprus  50, Czechoslovakia,  51, Denmark  52, Dominican Republic  53, Ecuador  54, Egypt  55, El Salvador  56, Equatorial Guinea  57, Eritrea  58, Estonia  59, Ethiopia  60, Fiji  61, Finland  62, France  63, French Guyana  64, Gabon  65, Gambia  66, Georgia  67, Germany  68, Ghana  69, Greece  70, Greenland  71, Guatemala  72, Guinea  73, Guyana  74, Haiti  75, Honduras  76, Hong Kong  77, Hungary  78, Iceland  79, India  80, Indonesia  81, Iran  82, Iraq  83, Ireland  84, Israel  85, Italy  86, Jamaica  87, Japan  88, Jordan  89, Kazakhstan  90, Kenya  91, Kosovo  92, Kuwait  93, Kyrgyzstan  94, Laos  95, Latvia  96, Lebanon  97, Liberia  98, Libya  99, Liechtenstein  100, Lithuania  101, Luxembourg  102, Macedonia  103, Madagascar  104, Malawi  105, Malaysia  106, Maldives  107, Mali  108, Malta  109, Mauritius  110, Mexico  111, Moldova  112, Monaco  113, Mongolia  114, Montenegro  115, Morocco  116, Mozambique  117, Myanmar  118, Multiple  119, Namibia  120, Nepal  121, Netherlands  122, New Zealand  123, Nicaragua  124, Niger  125, Nigeria  126, North Korea  127, North Yemen  128, Norway  129, Oman  130, Pakistan  131, Palestine  132, Panama  133, Papua New Guinea  134, Paraguay  135, Peru  136, Philippines  137, Poland  138, Portugal  139, Puerto Rico  140, Qatar  141, Romania  142, Russia  143, Rwanda  144, Samoa  145, San Marino  146, Saudi Arabia  147, Senegal  148, Serbia  149, Seychelles  150, Sierra Leone  151, Singapore  152, Slovakia  153, Slovenia  154, Solomon Islands  155, Somalia  156, South Africa  157, South Korea  158, South Sudan  159, South Yemen  160, Spain  161, Sri Lanka  162, Sudan  163, Suriname  164, Swaziland  165, Sweden  166, Switzerland  167, Syria  168, Tajikistan  169, Tanzania  170, Thailand  171, Tibet  172, Togo  173, Tunisia  174, Turkey  175, Turkmenistan  176, Uganda  177, Ukraine  178, United Arab Emirates  179, United Arab Republic  180, United Kingdom  181, United States of America  182, Uruguay  183, Uzbekistan  184, Venezuela  185, Vietnam  186, Yemen  187, Yugoslavia  188, Zambia  189, Zanzibar  190, Zimbabwe  191, Sao Tome and Principe  200, More than one country  888, Other |
| region | Region or comments from "country": |  |
| q1\_female | Number of females who remained asymptomatic throughout infection: |  |
| q1\_male | Number of males who remained asymptomatic throughout infection: |  |
| q1\_age\_median | Median age of all people who remained asymptomatic throughout infection: |  |
| q1\_age\_iqr | IQR for age of all people who remained asymptomatic throughout infection: |  |
| fup\_\_\_1 | Duration of follow-up time (choose all that apply): | 1, 14 days after the last possible exposure date |
| fup\_\_\_2 | Duration of follow-up time (choose all that apply): | 2, 7 days after diagnosis |
| fup\_\_\_3 | Duration of follow-up time (choose all that apply): | 3, Until negative PCR result |
| fup\_\_\_4 | Duration of follow-up time (choose all that apply): | 4, >7 days after diagnosis |
| risk\_of\_bias\_update\_3\_complete | Complete? | 0, Incomplete  1, Unverified  2, Complete |
| rob\_1 | (Consensus) Question 1- Was the sample invited to participate a close or true representation of the target population? | 1, High  2, Unclear  3, Low |
| rob\_1\_c2 | (Consensus) Question 1- Was the sample invited in cluster 2 to participate a close or true representation of the target population? | 1, High  2, Unclear  3, Low |
| rob\_2 | (Consensus) Q2- The characteristics of non-respondents, if any, who were eligible are similar to those who participated in the study? | 1, High  2, Unclear  3, Low |
| rob\_2\_c2 | (Consensus) Q2- The characteristics of non-respondents, if any, who were eligible are similar to those who participated in the study for cluster 2? | 1, High  2, Unclear  3, Low |
| rob\_3 | (Consensus) Q3- Was the assessment of symptoms status adequate? | 1, High  2, Unclear  3, Low |
| rob\_3\_c2 | (Consensus) Q3- Was the assessment of symptoms status adequate for cluster 2? | 1, High  2, Unclear  3, Low |
| rob\_4 | (Consensus) Q4- Based on the method symptoms were collected, is there a risk of recall bias? | 1, High  2, Unclear  3, Low |
| rob\_4\_c2 | (Consensus) Q4- Based on the method symptoms were collected, is there a risk of recall bias for cluster 2? | 1, High  2, Unclear  3, Low |
| rob\_5 | (Consensus) Q5- Is there a risk that asymptomatic status was misclassified? | 1, High  2, Unclear  3, Low |
| rob\_5\_c2 | (Consensus) Q5- Is there a risk that asymptomatic status was misclassified in cluster 2? | 1, High  2, Unclear  3, Low |
| rob\_6 | (Consensus) Q6- Is there a risk of incomplete or selective reporting of symptoms status? | 1, High  2, Unclear  3, Low |
| rob\_6\_c2 | (Consensus) Q6- Is there a risk of incomplete or selective reporting of symptoms status in cluster 2? | 1, High  2, Unclear  3, Low |
| agerange\_\_\_1 | Age range of asymptomatic  Select one or more if applicable | 1, Children (< 18 years) |
| agerange\_\_\_2 | Age range of asymptomatic  Select one or more if applicable | 2, Adults (18 - 65 years) |
| agerange\_\_\_3 | Age range of asymptomatic  Select one or more if applicable | 3, Older adults (>65 years) |
| agerange\_\_\_4 | Age range of asymptomatic  Select one or more if applicable | 4, All ages |
| agerange\_\_\_5 | Age range of asymptomatic  Select one or more if applicable | 5, Not Reported |